Exit

Health Condition

Pain

About This Condition

Pain is a sensation that is transmitted from an area of tissue damage or stress along the sensory nerves to the brain. The brain interprets the information as the sensation of pain. 

Substances that decrease pain either interfere with the ability of nerves to conduct messages, or alter the brain’s capacity to receive sensations.

Pain may be a symptom of an underlying pathological condition, such as inflammation. It may also be due to other causes, such as bruising, infection, burns, headaches, and sprains and strains. Use caution when treating pain without understanding its cause—this may delay diagnosis of conditions that could continue to worsen without medical attention.

Symptoms

Symptoms of pain include discomfort that is often worsened by movement or pressure and may be associated with irritability, problems sleeping, and fatigue. People with pain may have uncomfortable sensations described as burning, sharp, stabbing, aching, throbbing, tingling, shooting, dull, heavy, and tight.

Other Therapies

Some severe painful conditions might require surgical treatments to disrupt the pain signal.

References

1. Santos AR, Calixto JB. Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice. Neurosci Lett. 1997;235:73-6.

2. Otsuki T, Nakahama H, Niizuma H, Suzuki J. Evaluation of the analgesic effects of capsaicin using a new rat model for tonic pain. Brain Res 1986;365:235-40.

3. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999;81:135-45.

4. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997;73:123-39 [review].

5. Hautkappe M, Roizen MF, Toledano A, et al. Review of the effectiveness of capsaicin for painful cutaneous disorders and neural dysfunction. Clin J Pain 1998;14:97-106 [review].

6. Fusco BM, Giacovazzo M. Peppers and pain. The promise of capsaicin. Drugs 1997;53:909–14 [review].

7. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg 1998;86:579-83.

8. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994;46:517-22 [review].

9. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 1997;15:2974-80.

10. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995;7:317-28 [review].

11. Haze JJ. Toward an understanding of the rationale for the use of dietary supplementation for chronic pain management: the serotonin model. Cranio 1991;9:339-43.

12. Leiberman HR, Corkin S, Spring RJ, et al. Mood, performance and pain sensitivity: changes induced by food constituents. J Psychiatr Res 1982;17:135-45.

13. Shpeen SE, Morse DR, Furst ML. The effect of tryptophan on post-operative endodontic pain. Oral Surg Oral Med Oral Pathol 1984;58: 446-9.

14. Ekblom A, Hansson P, Thomsson M. L-tryptophan supplementation does not affect postoperative pain intensity or consumption of analgesics. Pain 1991;44:249-54.

15. Ceccherelli F, Diani MM, Altafini L, et al. Postoperative pain treated by intravenous L-tryptophan: a double-blind study versus placebo in cholecystectomized patients. Pain 1991;47:163-72.

16. Seltzer S, Stoch R, Marcus R, Jackson E. Alteration of human pain thresholds by nutritional manipulation and L-tryptophan supplementation. Pain 1982;13:385-93.

17. Mitchell MJ, Daines GE, Thomas BL. Effect of L-tryptophan and phenylalanine on burning pain threshold. Phys Ther 1987;67:203-5.

18. Seltzer S, Dewart D, Pollack RL, Jackson E. The effects of dietary tryptophan on chronic maxillofacial pain and experimental pain tolerance. J Psychiatr Res 1982-1983;17:181-6.

19. Brady JP, Cheatle MD, Ball WA. A trial of L-tryptophan in chronic pain syndrome. Clin J Pain 1987;3:39-43.

20. Stockstill JW, McCall WD Jr, Gross AJ, Piniewski B. The effect of L-tryptophan supplementation and dietary instruction on chronic myofascial pain. J Am Dent Assoc 1989;118:457-60.

21. Lin DZ, Fang YS. Modern Study and Application of Materia Medica. Hong Kong: China Ocean Press, 1990, 323-5.

22. Ehrenpreis S. Analgesic properties of enkephalinase inhibitors: animal and human studies. Prog Clin Biol Res 1985;192:363-70.

23. Guisti P, Carrara M, Cima L, Borin G. Antinociceptive effect of some carboxypeptidase A inhibitors in comparison with D-phenylalanine. Eur J Pharmacol 1985;116:287-92.

24. Walsh NE, Ramamurthy S, Schoenfeld LS, Hoffman J. D-phenylalanine was not found to exhibit opiod receptor mediated analgesia in monkeys. Pain 1986;26:409-10.

25. Ehrenpreis S, Balagot R, Comaty JE, Myles SB. Naloxonr reversible analgesia in mice produced by D-phenylalanine and hydrocinnamic acid, inhibitors of carboxypeptidase A. In Bonica JJ, et al., eds. Advances in Pain Research and Therapy, Vol. 3. New York: Raven Press, 1979.

26. Ehrenpreis S. Pharmacology of enkephalinase inhibitors: animal and human studies. Acupunct Electrother Res. 1985;10:203-8.

27. Balagot RC, Ehrenpreis S, Kubota K, Greenberg J. Analgesia in mice and humans by D-phenylalanine: Relation to inhibition of enkephalin degradation and enkephalin levels. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds., Advances in Pain Research and Therapy, Vol 5. New York: Raven Press, 1983, 289-93.

28. Mitchell MJ, Daines GE, Thomas BL. Effect of L-tryptophan and phenylalanine on burning pain threshold. Phys Ther 1987;67:203-5.

29. D'Alessandro R. D-Phenylalanine does not affect nociceptive, flexion reflex thresholds in normal humans. Anesth Analg 1983;62:857-8.

30. Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds., Advances in Pain Research and Therapy, Vol 5. New York: Raven Press, 1983, 305-8.

31. Donzelle G, Bernard L, Deumier R, et al. Curing trial of complicated oncologic pain by D-phenylalanine. Anesthesie, Analgesie, Reanimation 1981;38:655-8 [in French].

32. Walsh NE, Ramamurthy S, Schoenfeld LS, Hoffman J. Analgesic effectiveness of D-phenylalanine in chronic pain patients. Arch Phys Med Rehabil 1986;67:436-9.

33. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1981;1:229-32.

34. Kitade T, Minamikawa M, Nawata T, et al. An experimantal study on the enhancing effects of phenylalanine on acupuncture analgesia. Am J Chin Med 1981;9:243-8.

35. Takeshige C, Mera H, Hisamitsu T, et al. Inhibition of the analgesia inhibitory system by D-phenylalanine and proglumide. Brain Res Bull 1991;26:385-91.

36. Kitade T, Odahara Y, Shinohara S, et al. Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia by D-phenylalanine (first report)—effect on pain threshold and inhibition by naloxone. Acupunct Electrother Res 1988;13:87-97.

37. Kitade T, Odahara Y, Shinohara S, et al. Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia bu D-phenylalanine (2nd report)—schedule of administration and clinical effects in low back pain and tooth extraction. Acupunct Electrother Res 1990;15:121-35.

38. Murray MT. The Healing Power of Herbs. Rocklin, CA: Prima Publishing, 1995.

39. Santos AR, Filho VC, Yunes RA, et al. Analysis of the mechanisms underlying the antinociceptive effects of extracts of plants from the genus Phyllanthus. Gen Pharmacol 1995;26:1499-506.

40. Cechinel Filho V, Santos AR, De Campos RO, et al. Chemical and pharmacological studies of Phyllanthus caroliniensis in mice. J Pharm Pharmacol 1996;48:1231-6.

41. Miguel OG, Calixto JB, Santos Ar, et al. Chemical and preliminary analgesic evaluation of geraniin and furosin isolated from Phyllanthus sellowianus, Planta Med 1996;62:146-9.

42. Syamasundar KV, Singh B, Thakur RS, et al. Antihepatotoxic principles of Phyllanthus niruri herbs. J Ethnopharmacol 1985;14:41-4.

43. Murray MT. The Healing Power of Herbs. Rocklin, CA: Prima Publishing, 1995.

44. Hanck A, Weiser H. Analgesic and anti-inflammatory properties of vitamins. Int J Vitam Nutr Res Suppl 1985;27:189-206.

45. Hieber H. Treatment of vertebragenous pain and sensitivity disorders using high doses of hydroxocobalamin. Med Monatsschr 1974;28:545-8 [in German].

46. Hedner T, Everts B. The early clinical history of salicylates in rheumatology and pain. Clin Rheumatol 1998;17:17-25.

47. Cherng CH, Wong CS, Ho ST. Spinal actions of non-steroidal anti-inflammatory drugs. Acta Anaesthesiol Sin 1996;34:81-8.

48. Robbers JE, Tyler VE. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York: Haworth Press, 1999, 200-4.

49. Tapio D, Hymes AC. New Frontiers in TENS. Minnetonka, MN: LecTec Corporation, 1987, 63-9.

50. Nicholas JJ. Physical modalities in rheumatologic rehabilitation. Arch Phys Med Rehabil 1994;75:994-9.

51. Gersh, MR. Transcutaneous electrical nerve stimulation (TENS) for management of pain and sensory pathology. In Electrotherapy in Rehabilitation. Philadelphia: F.A. Davis Company, 1992.

52. Long DM. Fifteen years of of transutaneous electrical stimulation for pain control. Stereotact Funct Neurosurg 1991;56:2-19.

53. Carroll D, Tramer M, McQuay H, et al. Randomization is important in studies with pain outcomes: systemic review of transcutaneous electrical nerve stimulation in acute postoperative patients. Br J Anaesth 1996;77:798-803.

54. Oliveri AC, Clelland JA, Jackson J, Knowles C. Effects of auricular transcutaneous electrical nerve stimulation on experimental pain threshold. Phys Ther 1986;66:12-6.

55. Lander J, Fowler-Kerry S. TENS for children's procedural pain. Pain 1993;52:209-16.

56. Long DM. Current status of electrical stimulation on the nervous system for the relief of chronic pain. Surg Neurol 1998;49:142-4.

57. Robin O, Vinard H, Vernet-Maury E, Saumet JL. Influence of sex and anxiety on pain threshold and tolerance. Funct Neurol 1987;2:173-9.

58. Rybarczyk B, DeMarco G, DeLaCruz M, Lapidos S. Comparing mind-body wellness interventions for older adults with chronic illness: classroom versus home instruction. Behav Med 1999;24:181-90.

59. U.S. Department of Health and Human Services. Public Health Service. Acupuncture. NIH Consensus Statement 1997;15:1-34.

60. Vernon H. Qualitative review of studies of manipulation-induced hypoalgesia. J Manipulative Physiol Ther 2000;23:134-8.

61. Glover JR, Morris JG, Khosla T. Back pain: a randomized clinical trial of rotational manipulation of the trunk. Br J Indust Med 1974;31:59-64.

62. Terrett ACJ, Vernon HT. Manipulation and pain tolerance: a controlled study of the effect of spinal manipulation on paraspinal cutaneous pain tolerance levels. Am J Phys Med 1984;63:217-25.

63. Vernon HT, Aker P, Burns S, et al. Pressure pain threshold evaluation of the effect of spinal manipulation in the treatment of chronic neck pain: a pilot study. J Manipulative Physiol Ther 1990;13:13-6.

64. Vicenzino B, Collins D, Benson H, Wright A. The initial effects of a cervical spine manipulative physiotherapy treatment on the pain and dysfunction of lateral epicondylagia. Pain 1996;68:69-74.

65. Cote P, Mior SA. The short-term effect of a spinal manipulation on pain/pressure threshold in patients with chronic mechanical low back pain. J Manipulative Physiol Ther 1994;17:36-48.

66. Vernon HT, Dhami MS, Howley, TP, et al. Spinal manipulation and B-endorphin: a controlled study of the effect of a spinal manipulation on plasma B-endorphin levels in normal males. J Manipulative Physiol Ther 1986;9:115-23.

67. Christian GF, Stanton GJ, Sissons D, et. al. Immunoreactive ACTH, B-endorphin and cortisol levels in plasma following spinal manipulative therapy. Spine 1988;13:141-7.

68. Sanders GE, Reinnert O, Pepe R, et al. Chiropractic adjustive manipulation on subjects with acute low back pain: visual analogue scores and plasma b-endorphin levels. J Manipulative Physiol Ther 1990;13:391-5.

69. Lang EV, Benotsch EG, Fick LJ, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 2000;355:1486-90.

70. Pradalier A, Willer JC, Dry J. Pain sensitivity in obese individuals. Ann Med Interne (Paris) 1982;133:528-31.

71. Guieu R, Blin O, Pouget J, Serratrice G. Nociceptive threshold and physical activity. Can J Neurol Sci 1992;19:69-71.

72. Fordyce W, McMahon R, Rainwater G, et al. Pain complaint—exercise performance relationship in chronic pain. Pain 1981;10:311-21.

73. Schwarz L, Kindermann W. Changes in beta-endorphin levels in response to aerobic and anaerobic exercise. Sports Med 1992;13:25-36 [review].

74. Ferrell BA, Josephson KR, Pollan AM, et al. A randomized trial of walking versus physical methods for chronic pain management. Aging (Milano) 1997;9:99-105.

75. McCain GA. Nonmedicinal treatments in primary fibromyalgia. Rheum Dis Clin North Am 1989;15:73-90.

76. Kottke TE, Caspersen CJ, Hill CS. Exercise in the management and rehabilitation of selected chronic diseases. Prev Med 1984;13:47-65 [review].

77. Cowan P, Lovasik DA. American Chronic Pain Association: strategies for surviving chronic pain. Orthop Nurs 1990;9:47-9 [review].

Copyright © 2018 Healthnotes, Inc. All rights reserved. www.healthnotes.com

Learn more about Healthnotes, the company.

The information presented by Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2018.